- Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete Response Rate of 50% at Day ≥ 28 - Dosed First Patient in CD19-Targeted Phase 1 Clinical Trial with PBCAR19B Immune-Evading Stealth Cell - Precision to Host First In Vivo Gene